“…In multiple pre-clinical studies, they have been shown to activate antigen-specific CD8 + T cell responses [15,19,26,27] and generate protective immunity in tumor models, e.g., B16-OVA melanoma [7,13,19,23,26,27], and against multiple infectious diseases, e.g., H1N1 influenza [11], Listeria monocytogenes [7,12], Trypanosoma cruzi [13] and Mycobacterium tuberculosis [14]. When compared to commonly used commercial adjuvants, such as Poly(I:C) or Montanide, archaeal lipid vaccines were found to elicit equal or greater antigen specific CD8 + T cell-mediated cytotoxicity and IgG responses [10]. SLA-based archaeosomes can also induce local cytokine production at the site of injection even in the absence of an antigen [19].…”